First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.

Long awaiting head to head data of BTK in CLL. Aca was noninferior to Ibr with a median PFS of 38.4 mo in both arms. Although acala had less afib then ibr (9.4% vs 16.0%), afib was still prevalent. Overall, better tolerated but requires BID administration.

Read the full article here

Related Articles